1. The authors plan to include randomized controlled trials (RCTs), case-control studies, and cohort studies. RCTs are an understandable type of study to compare different types of anesthesia, while the other study types may be less common. It would help to have a preliminary estimate of how many studies of each type one might fine. A preliminary literature screen might give at least a lower bound for these numbers. 
GENERAL COMMENTS
You will be comparing general anesthesia to "techniques other than general anesthesia". You mention inhalational agents compared to propofol in terms of the risk of cancer recurrence. You should consider the fact that general anesthesia can be performed with inhalational agents, propofol, or a combination. In addition, many regional anesthetic techniques (neuraxial block, peripheral nerve block) may be accompanied by propofol sedation.
VERSION 1 -AUTHOR RESPONSE
Reviewer: 1
Reviewer Name: Matt Cooper Institution and Country: Telethon Kids Institute, Australia 1-With survival as the outcome, presumably some studies will present Hazard Ratios as opposed to outcomes from logistic regression (type) models. The authors should at least acknowledge this and mention their plan for handling this.
Response:
We appreciate the reviewer's comments. Initially, we decided to use risk ratio as a summary measure trying to include a greater number of studies with variable outcome definitions. Despite this, using hazards ratio (HR) when analysing time to event data is a standard statistical approach. Thereby, we reconsidered the use of HR in the meta-analysis and changed the protocol according to the reviewer's observations (lines 229-252).
Reviewer: 2
Reviewer Name: Dirk F Moore Institution and Country: Rutgers University Department of Biostatistics, USA.
1-The authors plan to include randomized controlled trials (RCTs), case-control studies, and cohort studies. RCTs are an understandable type of study to compare different types of anesthesia, while the other study types may be less common. It would help to have a preliminary estimate of how many studies of each type one might fine. A preliminary literature screen might give at least a lower bound for these numbers.
We appreciate the reviewer's comments. Impaired long-term survival after oncologic surgery was not even supposed as a possible adverse effect of an anaesthetic agent until some years ago. The investigation of the impact of anaesthetic techniques on melanoma surgery has been evaluated predominantly by dermatology and oncology publications. Systematic reviews including just RCTs are the standards for interventions, but our review in fact investigates the evidence for a potential harm of a specific anaesthetic technique. We decided to pool the results of randomised and non-randomised studies separately, to reduce the risk of unacceptable methodological heterogeneity (lines 229-230).
Reasons for performing a systematic review including non-randomised studies were included in the discussion section of manuscript as described below:
"The inclusion of cohort and case-control studies in the systematic review may be an expected source of bias. The association between anaesthetic technique and oncologic outcomes is not an anticipated endpoint of therapy; we aim to assess the possibility of unexpected harm in this systematic review. Unequivocal evidence of association of the anaesthetic technique with survival outcomes through randomised controlled trials may take several decades to establish. Such studies are expensive, take a long period of time, and require extensive follow-up. Hence, they are usually outside the scope of regular anaesthesia research. Decision-making is complex in the absence of such high-quality evidence, because evidence of harm is difficult to establish, though harm may occur in some instances. Therefore, observational data must be carefully assessed, especially when prospective data is inadequate. Adjusted data from observational studies by pooled analysis will be used to overcome confounding factors. Observational studies will not be combined with RCTs or quasi-randomised trials, limiting the influence of study design on the effects measured by this metaanalysis."
The main reason for performing a pilot search at the main databases is the calibration of the search strategy. Anticipation of the results while describing the protocol is not recommended. The preliminary search showed the viability of the protocol. The draft of the PubMed search strategy was reported as the Table 1 of the manuscript and the search strategies for the other databases were detailed on a supplementary file, according to PRISMA-P guidelines. That is why we do not include the description of preliminary pilot search in the manuscript. Despite this, the reference of some relevant research articles in this field may help the readers to understand that this research question has already been considered and that the systematic review has viability. This citation was included on the manuscript (lines 108-110).
2-The main outcomes are stated to be 5-year overall survival and 2-year disease-free survival. However, it is possible that the survival experience of these patients between general and other anesthesia may differ in ways not captured by these simple measures. For example, what if 2-year OS is better for one, and 7-year OS is better for the other treatment? Some allowance for this would be helpful.
Response:
Following the recommendations of some reviewers, the outcome measure for time to event data was changed to HR. We defined priority of the use of adjusted HR over the preferred follow-up period definitions, reducing the relevance of the follow-up time on the results (lines 239-241). The length of follow-up obeyed the recommendation of a consensus statement for perioperative outcome definitions.
Individual studies will be evaluated individually for risk of bias as stated in the protocol. If the OS in different time points leads to opposite results, clearly it breaks up the proportional hazards assumption, making the use of HR inappropriate. The presence of such discrepancy will impact the overall risk of bias, be subject of qualitative description, sensitivity analysis, and will influence the quality of evidence rating using GRADE.
3-Related to number 2, studies that are not randomized control studies may present comparisons as odds ratios rather than as survival curves. How will these be compared?
As previously reported in the original protocol (lines 237-238), "Case-control studies will be reported using odds ratio as the summary measure, and the data from this type of studies will be reported separately." Thus, case-control studies can only be compared quantitatively with other case-control studies, but not with investigation of different designs. The comparison of researches using incompatible outcome measures in the review will be performed only qualitatively. Response:
Interrater agreement of the screening process will be assessed by Cohen's kappa statistic measure. The kappa statistic is frequently used in systematic reviews to test interrater reliability. Cohen's kappa is a more robust method than percent agreement since it is an adjusted agreement considering the effect of chance. To dismiss any dubious interpretation of the protocol the text was changed to "Interrater agreement within the screening process will be assessed by using Cohen's kappa statistic in each step and reported" (lines 196-199) . It will be calculated as described in the Cochrane Handbook for Systematic Reviews of Interventions 7.2.6 section and the reference was included.
Reviewer: 3
Reviewer Name: Deepak Chawla Institution and Country: Government Medical College Hospital, Chandigarh, India 1-Authors plan to include both observational studies and randomized controlled trials in the systematic review. To address the likely heterogeneity, authors plan to do random effect metaanalysis. Is this sufficient to address possible baseline differences in the observational studies? Authors should enumerate possible confounding factors (e.g. stage of disease, age of patient and others authors have identified in the first paragraph of the introduction) and plan to conduct metaregression a priori if needed. Do you want to consider reporting hazard ratio?
We appreciate the reviewer's comments. The decision to perform a meta-analysis when there is important clinical and methodological heterogeneity is an important step when undergoing a systematic review, and unfortunately imply in a partly subjective judgement. We decided to pool the results of randomised and non-randomised studies separately, to reduce the risk of unacceptable methodological heterogeneity (lines 229-230). Reasons for performing a systematic review including non-randomised studies were included in the discussion section of manuscript as described below:
"The inclusion of cohort and case-control studies in the systematic review may be an expected source of bias. The association between anaesthetic technique and oncologic outcomes is not an anticipated endpoint of therapy; we aim to assess the possibility of unexpected harm in this systematic review.
Unequivocal evidence of association of the anaesthetic technique with survival outcomes through randomised controlled trials may take several decades to establish. Such studies are expensive, take a long period of time, and require extensive follow-up. Hence, they are usually outside the scope of regular anaesthesia research. Decision-making is complex in the absence of such high-quality evidence, because evidence of harm is difficult to establish, though harm may occur in some instances. Therefore, observational data must be carefully assessed, especially when prospective data is inadequate. Adjusted data from observational studies by pooled analysis will be used to overcome confounding factors. Observational studies will not be combined to RCT and quasirandomised studies, limiting the influence of different study designs on the effect measure of this meta-analysis."
An established risk of bias assessment strategy is an important tool to support this decision and is clearly defined in the protocol (lines 206-208) . The comparability between groups and the adjustment for confounding factors in non-randomised studies will be assessed using the Newcastle-Ottawa Scale. How clinical, methodological, and statistical heterogeneities will be used to define if pooling of results from individual studies is appropriate and the strategy for reporting the results is already documented on the original protocol (lines 218-221). Sensitivity analysis will help to find the impact of risk of bias in the results (lines 258-259).
Initially, we decided to use risk ratio as a summary measure trying to include a greater number of studies with variable outcome definitions. Despite this, using hazards ratio (HR) when analysing time to event data is a standard statistical approach. Thereby, we reconsidered the use of HR in the metaanalysis and changed the protocol according to the reviewer's observations (lines 234-237).
2-While selection of studies, will only those reporting long term outcome (survival) will be included or those reporting intermediate (duration of stay, in-hospital mortality) or surrogate (e.g. tumour markers) outcomes also included?
The study protocol does not use any outcome measure as an inclusion or exclusion criteria for original studies (lines 153-155):
"Outcomes are not part of the eligibility criteria to be included in the review. Results of individual studies not including predefined outcomes will be reported in the body of the article or in an appendix according to the authors conclusions regarding the relevance of individual studies."
It must be noticed that cutaneous melanoma surgery, especially at AJCC staging I to III, are low risk procedures involving a short hospital stay. Thereby, perioperative mortality and length of stay are not attractive outcomes. Also, tumour markers are not a routine way to follow melanoma disease progression as in prostate and colorectal cancers for instance.
Despite this, according to the "Systematic review and consensus definitions for standardised endpoints in perioperative medicine: postoperative cancer outcomes," published 2018 by the British Journal of Anaesthesia, some of the outcomes suggested above are included in the recommended list of outcomes. Although it is expected that some of that outcomes have not been reported in research regarding anaesthesia for malignant melanoma, it may be increased afterward since the publication of the consensus statement. Thereby, all the outcomes recommended by that publication that were not included as main outcomes were included in the systematic review as secondary outcomes: cancer health-related quality of life, time to tumour progression, distant disease-free survival, time to treatment failure, cancer specific survival, biochemical recurrence, return of intended oncologic therapy, and days alive and out of the hospital at 90 days. That adjustment of the systematic review protocol will be informed to the PROSPERO register as an amendment after the finish of the peer review process at BMJ-open (lines 127-130).
3-In study design-will pseudo/quasi randomized studies also be included?
Pseudo ou quasi-randomised studies are also eligible to the review. The protocol was adjusted (lines 141-142) to clarify the eligibility of both randomised, quasi-randomised, and non-randomised studies.
4-From the introduction, it seems that there is evidence that there may be differential effect of even different types of GA agents (e.g. halothane versus propofol or desflurane). There may be combination of anaesthetic techniques like GA + epidural (which some of references you quoted showing that may have favourable outcome). How will these be handled?
When the research group defined the intervention and comparison of the systematic review both the theoretical model and the articles retrieved on preliminary searches were considered. The reference of some relevant research articles in this field may help the readers to understand that this research question has already been considered and that the systematic review has viability. This citation was included in the manuscript (lines 108-110).
As indicated in the discussion, the anaesthetic factors that may influence survival and disease progression are probably tumour specific. This reflects surgical techniques and tumour biology unique to a specific cancer type. The anaesthetic techniques used in the intervention and comparison groups will be discussed in detail and will influence the interpretation of the results. The different anaesthetic techniques used in the control group will be used as parameters for subgroup analysis and metaregression (lines 259-262).
